Summary & Overview
CPT 87496: CMV Detection by Amplified Nucleic Acid Probe
CPT code 87496 represents a molecular diagnostic assay for cytomegalovirus (CMV) that uses an amplified nucleic acid probe technique. This test is clinically important because CMV can cause severe disease in neonates and immunocompromised individuals; accurate nucleic acid detection supports diagnosis, treatment decisions, and infection control. Nationally, molecular CMV testing is a core component of hospital and reference laboratory services for at-risk populations.
Key payers in typical coverage discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on clinical utility, typical service settings, and the role of this assay in caring for newborns and immunocompromised patients. The publication outlines what stakeholders commonly evaluate: clinical indications for testing, where the service is performed, and typical payer considerations. It also points to benchmarks and policy updates relevant to laboratory molecular testing when available.
The report provides a concise reference for billing and clinical teams seeking to align coding with laboratory workflows and payer conversations. Data not available in the input is noted where applicable, and the publication focuses on national implications rather than state-specific rules.
Billing Code Overview
CPT code 87496 describes a laboratory test for cytomegalovirus (CMV) using an amplified nucleic acid probe technique. The procedure is performed by a lab analyst and detects CMV genetic material, a pathogen that can cause severe illness in newborns and immunocompromised patients.
Service Type: Molecular diagnostic testing (amplified nucleic acid probe technique)
Typical Site of Service: Clinical laboratory or hospital laboratory setting, including specialized virology or molecular diagnostics labs where specimens from newborns or immunocompromised patients are analyzed.
Clinical & Coding Specifications
Clinical Context
A newborn infant in the neonatal intensive care unit (NICU) born to a mother with a positive cytomegalovirus (CMV) serology during pregnancy is evaluated for congenital infection. The infant presents with jaundice, petechiae, and low birth weight within the first week of life. A buccal swab or urine specimen is collected and sent to the hospital molecular diagnostics laboratory for nucleic acid amplification testing (NAAT) specific for CMV. The lab analyst performs 87496 using an amplified nucleic acid probe technique to detect CMV DNA or RNA. Results are reported to the neonatologist and infectious disease consultant; positive NAAT within the first 3 weeks of life supports congenital CMV and guides antiviral management and further audiology and neuroimaging evaluations.
Typical workflow:
-
Clinical team orders CMV NAAT (
87496) with specimen type and collection time noted. -
Specimen labeled and transported to molecular lab with chain-of-custody and accessioning.
-
Laboratory technologist/analyst performs specimen processing, nucleic acid extraction, amplification and probe-based detection per assay protocol.
-
Results reviewed by lab director or qualified technologist; positive/negative and semi-quantitative data (if available) are entered into the electronic medical record.
-
Result communicated to ordering clinician; result may prompt confirmatory testing, initiation of antiviral therapy in symptomatic neonates or immunocompromised adults, and public health or perinatal follow-up.